for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Merck & Co., Inc.

MRK.N

Latest Trade

72.04USD

Change

0.07(+0.10%)

Volume

2,580,489

Today's Range

71.87

 - 

72.41

52 Week Range

70.90

 - 

85.60

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
71.97
Open
72.33
Volume
2,580,489
3M AVG Volume
217.88
Today's High
72.41
Today's Low
71.87
52 Week High
85.60
52 Week Low
70.90
Shares Out (MIL)
2,531.37
Market Cap (MIL)
182,081.80
Forward P/E
12.99
Dividend (Yield %)
3.61

Next Event

Q3 2021 Merck & Co Inc Earnings Call

Latest Developments

More

HOOKIPA Collaborates With Merck To Evaluate HB-200 With Keytruda In Advanced Head And Neck Cancers

Merck Sees Potential U.S. Authorization For COVID-19 Drug Molnupiravir Before Year-End

Merck And Ridgeback Biotherapeutics Announce Initiation Of Pivotal Phase 3 Move-Ahead Study Evaluating Molnupiravir For Post-Exposure Prophylaxis Of Covid-19 Infection

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Merck & Co., Inc.

Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through two segments: Pharmaceutical and Animal Health. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products. Its human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations. The Animal Health segment develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species.

Industry

Biotechnology & Drugs

Contact Info

2000 Galloping Hill Rd

KENILWORTH, NJ

07033-1310

United States

+1.908.7404000

http://www.merck.com/

Executive Leadership

Kenneth C. Frazier

Executive Chairman of the Board

Robert M. Davis

President, Chief Executive Officer, Director

Caroline Litchfield

Chief Financial Officer, Executive Vice President

Franklin K. Clyburn

President, Human Health, Head of Human Health Commercial and Marketing

Dean Y. Li

President - Merck Research Laboratories

Key Stats

2.04 mean rating - 23 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

42.3K

2019

46.8K

2020

48.0K

2021(E)

46.8K
EPS (USD)

2018

4.340

2019

5.190

2020

5.940

2021(E)

5.531
Price To Earnings (TTM)
38.07
Price To Sales (TTM)
3.87
Price To Book (MRQ)
5.47
Price To Cash Flow (TTM)
22.22
Total Debt To Equity (MRQ)
79.66
LT Debt To Equity (MRQ)
72.18
Return on Investment (TTM)
7.03
Return on Equity (TTM)
5.31

Latest News

Latest News

Merck, Pfizer's Wyeth settle pneumococcal vaccine patent dispute

Merck Sharp & Dohme Corp and Pfizer's Wyeth LLC subsidiary have resolved a patent dispute over their competing vaccines for preventing diseases including pneumonia and meningitis, according to a Delaware court filing.

BRIEF-Merck Sees Potential U.S. Authorization For COVID-19 Drug Molnupiravir Before Year-End

* MERCK CEO SAYS BUSINESS DEVELOPMENT IS A HIGH PRIORITY; WILL CONTINUE TO BE APPROPRIATELY AGGRESSIVE IN EVALUATING POTENTIAL TARGETS - MORGAN STANLEY CONF

Merck sees potential U.S. authorization for COVID-19 antiviral before year-end

Drugmaker Merck & Co Inc said on Monday it sees potential U.S. emergency use authorization for its experimental COVID-19 antiviral treatment, molnupiravir, before year-end.

Pfizer, Merck launch new trials of oral COVID-19 drugs

Pfizer Inc and Merck & Co Inc announced on Wednesday new trials of their experimental oral antiviral drugs for COVID-19 as the race to develop an easy-to-administer treatment for the potentially fatal illness heats up.

Merck begins late-stage trial of experimental COVID-19 drug

Merck & Co Inc and partner Ridgeback Biotherapeutics said on Wednesday they had begun enrolling patients in a late-stage trial of their experimental drug molnupiravir for prevention of COVID-19 infection.

Merck begins late-stage trial of experimental COVID-19 drug

Merck & Co Inc and partner Ridgeback Biotherapeutics said on Wednesday they had begun enrolling patients in a late-stage trial of their experimental drug molnupiravir for prevention of COVID-19 infection. (Reporting by Manas Mishra in Bengaluru; Editing by Krishna Chandra...

Merck initiates rolling submission to Health Canada for oral COVID-19 drug

U.S. drugmaker Merck & Co Inc has initiated a rolling submission to Health Canada for Molnupiravir, an oral antiviral therapy treatment for COVID-19, it said in a statement on Friday.

BRIEF-Australia's TGA Grants Provisional Determination To Merck Sharp & Dohme's Molnupiravir

* AUSTRALIA'S TGA: PROVISIONAL DETERMINATION MEANS TGA HAS MADE DECISION THAT MSD ELIGIBLE TO APPLY FOR PROVISIONAL REGISTRATION FOR MOLNUPIRAVIR IN ARTG

Germany Inc offers brighter outlook as recovery gathers pace

Some of Germany's best-known brands and industry bellwethers lifted their full-year sales and profit expectations on Thursday, citing a broad demand recovery from the effects of the pandemic.

Merck sees recovery in non-COVID vaccine demand as quarterly sales beat estimates

Merck & Co reported quarterly revenue on Thursday that topped Wall Street estimates, as sales of its Gardasil vaccine bounced back and demand for blockbuster cancer drug Keytruda remained strong.

BRIEF-Merck Exec Sees Late-Stage Data On COVID-19 Antiviral Drug In October

* MERCK & CO CEO SAYS CO HAS FINANCIAL FLEXIBILITY TO CONSIDER DEALS OF ALL SIZES

Merck profit nearly halves on Organon spin off

Merck & Co Inc on Thursday reported a 49% fall in second-quarter profit after it spun off its women's health and biosimilar assets into Organon in June. (Reporting by Manas Mishra in Bengaluru; Editing by Shounak Dasgupta)

U.S. FDA approves Merck's Keytruda combo for early breast cancer treatment

Merck & Co Inc said on Tuesday that the U.S. Food and Drug Administration approved its immunotherapy Keytruda as a treatment for an early form of a tough-to-treat breast cancer in combination with chemotherapy.

India's Hetero seeks emergency use nod for Merck's COVID-19 drug

India's Hetero Labs said on Friday it sought emergency use nod from the local regulator for Merck's COVID-19 drug molnupiravir, after interim data from a late-stage trial showed it helped reduce hospitalisations and speed up recovery in mild cases.

Five Indian drugmakers to jointly start local trial of Merck & Co's COVID-19 drug

Five Indian generic drugmakers, including Cipla and Dr Reddy's Laboratories, said on Tuesday they would jointly conduct a clinical trial in India for Merck & Co's experimental anti-viral drug to treat mild COVID-19 in non-hospitalised patients.

Five Indian drugmakers to jointly start trial of Merck & Co's COVID-19 drug

Five Indian generic drugmakers, including Cipla and Dr Reddy's Laboratories, said on Tuesday they would jointly conduct a clinical trial of Merck & Co's anti-viral drug to treat mild COVID-19 in non-hospitalised patients in India.

U.S. signs $1.2 billion deal for 1.7 million courses of Merck's experimental COVID-19 drug

Merck & Co Inc said on Wednesday the U.S. government has agreed to pay about $1.2 billion for 1.7 million courses of its experimental COVID-19 treatment, if it is proven to work in an ongoing large trial and authorized by U.S. regulators.

Merck says U.S. govt to buy about 1.7 mln courses of co's COVID-19 drug

Merck & Co Inc said on Wednesday the U.S. government has agreed to buy about 1.7 million courses of the company's experimental COVID-19 drug, molnupiravir, for about $1.2 billion, if it is authorized in the country. (Reporting by Manojna Maddipatla in Bengaluru; Editing...

AstraZeneca's Lynparza reduces relapse, death in breast cancer patients

AstraZeneca Plc's drug Lynparza reduced the risk of relapse and death in breast cancer patients with certain mutations in a late-stage trial, the British drugmaker said on Thursday.

Germany's Merck sees boost from labs supplies earnings

Germany's Merck on Wednesday said its Life Science business, a leading maker of biotech lab supplies and gear, saw core earnings jump more than 43% in the first quarter, driven by the pharma industry's efforts to fight the coronavirus pandemic.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up